{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:28:05Z","timestamp":1760909285600,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009142","name":"Cancer Care Ontario","doi-asserted-by":"publisher","award":["Clinical Programs and Quality Initiatives grants 2017 and 2018"],"award-info":[{"award-number":["Clinical Programs and Quality Initiatives grants 2017 and 2018"]}],"id":[{"id":"10.13039\/100009142","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s00520-021-06142-8","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T17:02:55Z","timestamp":1616173375000},"page":"5787-5795","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A prospective multi-centre, randomized study comparing the addition of tapering dexamethasone to other standard of care therapies for taxane-associated pain syndrome (TAPS) in breast cancer patients"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0738-2713","authenticated-orcid":false,"given":"Mark","family":"Clemons","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Demetrios","family":"Simos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Sienkiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terry","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Labib","family":"Zibdawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bassam","family":"Basulaiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arif","family":"Awan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean","family":"Fergusson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Vandermeer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deanna","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Hutton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eitan","family":"Amir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the REThinking Clinical Trials (REaCT) Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,19]]},"reference":[{"issue":"8","key":"6142_CR1","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1007\/s00520-016-3256-5","volume":"24","author":"R Fernandes","year":"2016","unstructured":"Fernandes R, Mazzarello S, Hutton B, Shorr R, Majeed H, Ibrahim MF, Jacobs C, Ong M, Clemons M (2016) Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer-a systematic review. Support Care Cancer 24(8):3633\u20133650. https:\/\/doi.org\/10.1007\/s00520-016-3256-5","journal-title":"Support Care Cancer"},{"key":"6142_CR2","unstructured":"Sanofi-Aventis (2017) Taxotere (docetaxel for injection). http:\/\/products.sanofi.ca\/en\/taxotere.pdf. Accessed September 27 2018"},{"issue":"15","key":"6142_CR3","first-page":"867","volume":"139","author":"S Eckhardt","year":"1998","unstructured":"Eckhardt S (1998) The effect of docetaxel on malignant tumors. Orv Hetil 139(15):867\u2013872","journal-title":"Orv Hetil"},{"issue":"10","key":"6142_CR4","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1200\/JCO.1995.13.10.2643","volume":"13","author":"JE Cortes","year":"1995","unstructured":"Cortes JE, Pazdur R (1995) Docetaxel. J Clin Oncol 13(10):2643\u20132655","journal-title":"J Clin Oncol"},{"issue":"10","key":"6142_CR5","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1200\/jco.1998.16.10.3426","volume":"16","author":"KA Semb","year":"1998","unstructured":"Semb KA, Aamdal S, Oian P (1998) Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol 16(10):3426\u20133432. https:\/\/doi.org\/10.1200\/jco.1998.16.10.3426","journal-title":"J Clin Oncol"},{"issue":"3","key":"6142_CR6","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1177\/1078155210367950","volume":"17","author":"JD Chouhan","year":"2011","unstructured":"Chouhan JD, Herrington JD (2011) Single premedication dose of dexamethasone 20 mg IV before docetaxel administration. J Oncol Pharm Pract 17(3):155\u2013159. https:\/\/doi.org\/10.1177\/1078155210367950","journal-title":"J Oncol Pharm Pract"},{"issue":"9","key":"6142_CR7","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1200\/jco.1997.15.9.3149","volume":"15","author":"MJ Piccart","year":"1997","unstructured":"Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, Bontenbal M, Awada A, Selleslags J, Van Vreckem A, Van Glabbeke M (1997) Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol 15(9):3149\u20133155. https:\/\/doi.org\/10.1200\/jco.1997.15.9.3149","journal-title":"J Clin Oncol"},{"issue":"10","key":"6142_CR8","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1007\/s00520-013-1842-3","volume":"21","author":"MJ Poi","year":"2013","unstructured":"Poi MJ, Berger M, Lustberg M, Layman R, Shapiro CL, Ramaswamy B, Mrozek E, Olson E, Wesolowski R (2013) Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review. Support Care Cancer 21(10):2679\u20132686. https:\/\/doi.org\/10.1007\/s00520-013-1842-3","journal-title":"Support Care Cancer"},{"issue":"4","key":"6142_CR9","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1007\/s00520-015-2941-0","volume":"24","author":"R Fernandes","year":"2016","unstructured":"Fernandes R, Mazzarello S, Majeed H, Smith S, Shorr R, Hutton B, Ibrahim MF, Jacobs C, Ong M, Clemons M (2016) Treatment of taxane acute pain syndrome (TAPS) in cancer patients receiving taxane-based chemotherapy-a systematic review. Support Care Cancer 24(4):1583\u20131594. https:\/\/doi.org\/10.1007\/s00520-015-2941-0","journal-title":"Support Care Cancer"},{"issue":"4","key":"6142_CR10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3747\/co.v17i4.562","volume":"17","author":"S Saibil","year":"2010","unstructured":"Saibil S, Fitzgerald B, Freedman OC, Amir E, Napolskikh J, Salvo N, Dranitsaris G, Clemons M (2010) Incidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: a retrospective, outcomes-based survey. Curr Oncol 17(4):42\u201347","journal-title":"Curr Oncol"},{"issue":"1","key":"6142_CR11","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00520-017-3836-z","volume":"26","author":"N Chiu","year":"2018","unstructured":"Chiu N, Zhang L, Dent R, Giotis A, van Draanen J, Gallo-Hershberg D, Chiu L, Chow R, Wan BA, Pasetka M, Stinson J, Stacey E, Verma S, Lam H, Chow E, DeAngelis C (2018) A prospective study of docetaxel-associated pain syndrome. Support Care Cancer 26(1):203\u2013211. https:\/\/doi.org\/10.1007\/s00520-017-3836-z","journal-title":"Support Care Cancer"},{"issue":"11","key":"6142_CR12","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1007\/s00520-015-2731-8","volume":"23","author":"C Jacobs","year":"2015","unstructured":"Jacobs C, Hutton B, Mazzarello S, Smith S, Joy A, Amir E, Ibrahim MF, Gregario N, Daigle K, Eggert L, Clemons M (2015) Optimisation of steroid prophylaxis schedules in breast cancer patients receiving docetaxel chemotherapy-a survey of health care providers and patients. Support Care Cancer 23(11):3269\u20133275. https:\/\/doi.org\/10.1007\/s00520-015-2731-8","journal-title":"Support Care Cancer"},{"key":"6142_CR13","doi-asserted-by":"crossref","unstructured":"Hilton J, Mazzarello S, Fergusson D, Joy A, Robinson A, Arnaout A, Hutton B, Vandermeer L, Clemons M (2016) Novel methodology for comparing standard-of-care interventions in patients with cancer. J Oncol Pract 12(12):\u2013e1024","DOI":"10.1200\/JOP.2016.013474"},{"key":"6142_CR14","unstructured":"ClinicalTrials.gov (2017) Comparing tapering low dose dexamethasone to other standard of care therapies for TAPS in breast cancer patients (REaCT-TAPS). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03348696. Accessed September 27 2018"},{"issue":"3","key":"6142_CR15","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","volume":"11","author":"DF Cella","year":"1993","unstructured":"Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J et al (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11(3):570\u2013579","journal-title":"J Clin Oncol"},{"issue":"4","key":"6142_CR16","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1002\/cncr.11578","volume":"98","author":"D Cella","year":"2003","unstructured":"Cella D, Peterman A, Hudgens S, Webster K, Socinski MA (2003) Measuring the side effects of taxane therapy in oncology: the functional assesment of cancer therapy-taxane (FACT-taxane). Cancer 98(4):822\u2013831. https:\/\/doi.org\/10.1002\/cncr.11578","journal-title":"Cancer"},{"issue":"9","key":"6142_CR17","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/0959-8049(94)90182-1","volume":"30A","author":"RK Portenoy","year":"1994","unstructured":"Portenoy RK, Thaler HT, Kornblith AB, Lepore JM, Friedlander-Klar H, Kiyasu E, Sobel K, Coyle N, Kemeny N, Norton L et al (1994) The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer (Oxford, England: 1990) 30A(9):1326\u20131336","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"issue":"1","key":"6142_CR18","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/cncr.21567","volume":"106","author":"SC McMillan","year":"2006","unstructured":"McMillan SC, Small BJ, Weitzner M, Schonwetter R, Tittle M, Moody L, Haley WE (2006) Impact of coping skills intervention with family caregivers of hospice patients with cancer: a randomized clinical trial. Cancer 106(1):214\u2013222","journal-title":"Cancer"},{"key":"6142_CR19","doi-asserted-by":"crossref","unstructured":"McMillan SC, Small BJ (2002) Symptom distress and quality of life in patients with cancer newly admitted to hospice home care. Oncol Nurs Forum 10","DOI":"10.1188\/02.ONF.1421-1428"},{"issue":"2","key":"6142_CR20","doi-asserted-by":"publisher","first-page":"108","DOI":"10.4103\/0973-1075.84531","volume":"17","author":"SP Kumar","year":"2011","unstructured":"Kumar SP (2011) Utilization of brief pain inventory as an assessment tool for pain in patients with cancer: a focused review. Indian J Palliat Care 17(2):108\u2013115","journal-title":"Indian J Palliat Care"},{"issue":"7","key":"6142_CR21","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1097\/MLR.0000000000000283","volume":"55","author":"JM Ramos-Go\u00f1i","year":"2017","unstructured":"Ramos-Go\u00f1i JM, Pinto-Prades JL, Oppe M, Cabas\u00e9s JM, Serrano-Aguilar P, Rivero-Arias O (2017) Valuation and modeling of EQ-5D-5L health states using a hybrid approach. Med Care 55(7):e51\u2013e58","journal-title":"Med Care"},{"issue":"7","key":"6142_CR22","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/sj.bjc.6603048","volume":"94","author":"J Vardy","year":"2006","unstructured":"Vardy J, Chiew KS, Galica J, Pond GR, Tannock IF (2006) Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 94(7):1011\u20131015. https:\/\/doi.org\/10.1038\/sj.bjc.6603048","journal-title":"Br J Cancer"},{"issue":"9","key":"6142_CR23","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1007\/s00520-018-4161-x","volume":"26","author":"R Fernandes","year":"2018","unstructured":"Fernandes R, Mazzarello S, Joy AA, Pond GR, Hilton J, Ibrahim MFK, Canil C, Ong M, Stober C, Vandermeer L, Hutton B, da Costa M, Damaraju S, Clemons M (2018) Taxane acute pain syndrome (TAPS) in patients receiving chemotherapy for breast or prostate cancer: a prospective multi-center study. Support Care Cancer 26(9):3073\u20133081. https:\/\/doi.org\/10.1007\/s00520-018-4161-x","journal-title":"Support Care Cancer"},{"issue":"1","key":"6142_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clgc.2016.07.018","volume":"15","author":"R Fernandes","year":"2017","unstructured":"Fernandes R, Mazzarello S, Hutton B, Shorr R, Ibrahim MF, Jacobs C, Ong M, Clemons M (2017) A systematic review of the incidence and risk factors for taxane acute pain syndrome in patients receiving taxane-based chemotherapy for prostate cancer. Clin Genitourin Cancer 15(1):1\u20136","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"6142_CR25","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s00520-018-4408-6","volume":"27","author":"M Clemons","year":"2019","unstructured":"Clemons M, Mazzarello S, Hilton J, Joy A, Price-Hiller J, Zhu X, Verma S, Kehoe A, Ibrahim MF, Sienkiewicz M, Stober C, Vandermeer L, Hutton B, Mallick R, Fergusson D (2019) Feasibility of using a pragmatic trials model to compare two primary febrile neutropenia prophylaxis regimens (ciprofloxacin versus G-CSF) in patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer (REaCT-TC). Support Care Cancer 27(4):1345\u20131354. https:\/\/doi.org\/10.1007\/s00520-018-4408-6","journal-title":"Support Care Cancer"},{"issue":"2","key":"6142_CR26","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s10549-017-4604-y","volume":"168","author":"MFK Ibrahim","year":"2018","unstructured":"Ibrahim MFK, Hilton J, Mazzarello S, Fergusson D, Hutton B, Robinson A, Califaretti N, Hsu T, Gertler S, Mates M, Stober C, Vandermeer L, Mallick R, Clemons M (2018) A multi-center pragmatic, randomized, feasibility trial comparing standard of care schedules of filgrastim administration for primary febrile neutropenia prophylaxis in early-stage breast cancer. Breast Cancer Res Treat 168(2):371\u2013379. https:\/\/doi.org\/10.1007\/s10549-017-4604-y","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"6142_CR27","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1056\/NEJMhle1312508","volume":"370","author":"SY Kim","year":"2014","unstructured":"Kim SY, Miller FG (2014) Informed consent for pragmatic trials\u2014the integrated consent model. N Engl J Med 370(8):769\u2013772. https:\/\/doi.org\/10.1056\/NEJMhle1312508","journal-title":"N Engl J Med"},{"issue":"9","key":"6142_CR28","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1001\/jama.2014.18528","volume":"313","author":"SY Kim","year":"2015","unstructured":"Kim SY, Miller FG (2015) Varieties of standard-of-care treatment randomized trials: ethical implications. JAMA 313(9):895\u2013896. https:\/\/doi.org\/10.1001\/jama.2014.18528","journal-title":"JAMA"},{"key":"6142_CR29","unstructured":"Health\"; OMo (2017) Schedule of Benefits for Physician Services Under the Health Insurance Act 2015"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06142-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-021-06142-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06142-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T09:11:27Z","timestamp":1630487487000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-021-06142-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,19]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["6142"],"URL":"https:\/\/doi.org\/10.1007\/s00520-021-06142-8","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2021,3,19]]},"assertion":[{"value":"11 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and the Ontario Cancer Research Ethics Board and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Integrated informed consent was obtained from all trial participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The participants gave consent to de-identified publication of aggregate study results.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MC reports personal fees (honoraria) from Pfizer, outside the submitted work. TN reports personal fees (honoraria) from ARIAD, Takeda and Boehringer-Ingelheim, outside the submitted work. AA has participated on an advisory board for Novartis, Eli Lily, Exactis innovation and Pfizer, has received honoraria from Apobiologix and Roche and has received travel funds from Roche. BH reports consulting fees from Cornerstone Research, outside the submitted work. All other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}